As tacrolimus increases the risk of diabetes via reductions in insulin secretion and inhibition of insulin gene expression stimulus by hyperglycemia [52,53], long term monitoring blood glucose level is important for patients with IMN treated with this agent. This evidence concerns the gene INS and Hyperglycemia.